Buscar
Mostrando ítems 1-4 de 4
Novel Soluplus®-TPGS mixed micelles for encapsulation of paclitaxel with enhanced in vitro cytotoxicity on breast and ovarian cancer cell lines
(Elsevier Science, 2016-04)
The aim of this work was to develop mixed micelles based on two biocompatible copolymers of polyvinyl caprolactam-polyvinyl acetate-polyethylene glycol (Soluplus®) and D-α-tocopheryl polyethylene-glycol 1000 succinate ...
Mixed micelles for encapsulation of doxorubicin with enhanced in vitro cytotoxicity on breast and ovarian cancer cell lines versus Doxil®
(Elsevier France-editions Scientifiques Medicales Elsevier, 2017-11)
Doxorubicin (DOX) is used as a “first-line” antineoplastic drug in ovarian and metastatic breast cancer. However, serious side effects, such as cardiotoxicity have been reported after DOX intravenous administration. Hence, ...
Paclitaxel and curcumin co-loaded mixed micelles: Improving in vitro efficacy and reducing toxicity against Abraxane®
(Editions Sante, 2021-04)
Paclitaxel (PTX) is one of the most effective antineoplastic drugs employed for breast and ovarian cancer therapy. However, the neurotoxicity associated with PTX administration represents one of its main drawbacks reducing ...
A glucose-targeted mixed micellar formulation outperforms Genexol in breast cancer cells
(Elsevier Science, 2017-05)
Breast cancer represents the top cancer among women, accounting 521.000 deaths per year. Development of targeted nanomedicines to breast cancer tissues represents a milestone to reduce chemotherapy side effects. Taking ...